Perthera AI

Excited to be at and wanted to share some news about Perthera AI. If you're in Chicago this weekend, stop by booth #26116 and say hello. We have lots to share!

At ASCO '23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics /PRNewswire/ -- ASCO 2023 – McCormick Place, In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect on July 1st,...

The Perthera AI Clinical Team is proud to to support the Colorectal Cancer Alliance in its mission to end colorectal cancer.

Did you know that In 2023, an estimated 153,020 people will be diagnosed with this highly preventable disease? They will join more than 1.4 million colorectal cancer patients and survivors living today. We go blue for them, their families, and their community.

New Category III CPT Code for Precision Oncology Decision Support Platform at Perthera

www.perthera.com

We are thrilled to announce a strategic partnership with Massive Bio to empower more cancer patients to find an appropriate clinical trial. Read more about how we are offering personalized therapies and accurate trial recommendations:

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations Massive Bio and Perthera.ai announced a partnership to empower more cancer patients to find an appropriate clinical trial, with the help of AI.

is a wrap and we are thrilled to have so many people stop by the booth to learn more about our new AI Analytics platform. Now available to Centers across the country:

PERTHERA AI ANALYTICS LAUNCHES IMPROVED ANALYTICS, CLINICAL TRIAL OPTIMIZATION AND PATIENT CARE MANAGEMENT TOOL AT ASCO Perthera AI’s proven data mining, analytics, optimization and care management platform now available for cancer centers to utilize for their own data analysis.

📍📍📍 Stop by Booth 27102 at the American Society of Clinical Oncology ( ) Annual Meeting in Chicago to experience our new RWE Analytics interface tool that advances data curation and trial selection; hear more about our ground-breaking research and collaborations; and meet the Perthera team, including our new President & CEO, Albert Kelley. Read more here: https://bit.ly/Perthera_ASCO

The FDA approved a new CAR-T therapy for multiple myeloma, a move that could ease strain on limited supplies of potentially lifesaving cancer therapies.

FDA approves second CAR-T cancer therapy to treat multiple myeloma, opening the door for greater access The FDA has approved a new CAR-T therapy for multiple myeloma, a move that could ease strain on limited supplies of potentially lifesaving cancer therapies.

Clinical trials often lack diversity. Here's how to fix that.

Prostate Cancer Diversity in Clinical Trials Helps To develop better prostate cancer treatments and more successful outcomes, more diverse clinical trials are necessary.

The Association of Community Cancer Centers (ACCC) has launched a set of resources designed to help healthcare facilities and professionals understand and implement precision oncology medicine at their organizations.

https://bit.ly/360qNYZ

bit.ly

"With pivotal clinical trials for new cancer blood tests – so-called ‘liquid biopsies’ – occurring in 2022, transformative change for the diagnostics surrounding CRC may be around the corner."

Landmark year ahead for colorectal cancer testing and liquid biopsies March is National Colorectal Cancer (CRC) Awareness Month, a time aimed at raising awareness for what is the world’s second leading cause of cancer death worldwide. With pivotal clinical trials for new cancer blood tests – so-called ‘liquid biopsies’ – occurring in 2022, transformative cha...